Atlas Trials

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

Clinical trial NCT06238921 · RECRUITING

Trial details

NCT number
NCT06238921
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Breast CancerTriple Negative Breast Cancer
Start date
2024-12-19
Primary completion
2027-02-01
Enrollment
31

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.